MARKET

GMDA

GMDA

Gamida Cell Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.000
-0.050
-1.23%
Closed 16:00 08/14 EDT
OPEN
4.000
PREV CLOSE
4.050
HIGH
4.140
LOW
3.940
VOLUME
172.85K
TURNOVER
--
52 WEEK HIGH
7.70
52 WEEK LOW
2.600
MARKET CAP
197.89M
P/E (TTM)
-5.4953
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GMDA stock price target is 15.83 with a high estimate of 20.00 and a low estimate of 13.00.

EPS

GMDA News

More
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 3d ago
Gamida Cell Q2 EPS $(0.37) Misses $(0.30) Estimate
Gamida Cell (NASDAQ:GMDA) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the
Benzinga · 3d ago
Gamida Cell Q2 EPS $(0.37) Misses $(0.30) Estimate
Gamida Cell (NASDAQ:GMDA) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the
Benzinga · 3d ago
Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and Webcast
Gamida Cell announced that it will report its second quarter 2020 financial results on Tuesday, August 11, 2020.
Business Wire · 08/04 12:31
Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?
Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.
Zacks · 07/23 15:09
Gamida Cell appoints COO
Gamida Cell (NASDAQ:GMDA) appoints Michele Korfin as chief operating and chief commercial officer. Ms. Korfin has over 20 years of experience in oncology,
seekingalpha · 07/21 17:14
Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer
Gamida Cell announced the appointment of Michele Korfin as chief operating and chief commercial officer.
Business Wire · 07/21 12:01
Has Gamida Cell (GMDA) Outpaced Other Medical Stocks This Year?
Is (GMDA) Outperforming Other Medical Stocks This Year?
Zacks · 07/20 15:30

Industry

Biotechnology & Medical Research
-0.56%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About GMDA

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).
More

Webull offers kinds of Gamida Cell Ltd stock information, including NASDAQ:GMDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GMDA stock methods without spending real money on the virtual paper trading platform.